Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION® Platform at the European Society of Medical Oncology Annual Congress
Median progression free survival (PFS) has not been reached in the cohort of patients with salivary gland cancer with PFS…